Alnylam Pharmaceuticals has had a successful third quarter in 2025, reportedly reaching peak profitability and record revenue growth. The company has also reiterated its buy recommendation and increased its price target due to strong Amvuttra sales. The company's recent performance has been commendably strong, with earnings surpassing estimates and an upgrade in revenue that has shifted its investment narrative positively. Despite a temporary drop in range, the company's resilience is evident in the significant growth recovery. The company has also made promising progress on its Nucresiran Phase 3 study for hATTR-PN. The impressive performance of Amvuttra has driven growth and raised guidance, while its pipeline continues to make progress. Alnylam's valuation post new partnerships, pipeline progress, and finance restructuring has been on the rise. Despite strong Q3 results and raised guidance, Alnylam's shares dropped 4%, but the price target was increased by various financial groups. Notably, Alnylam has joined the Alliance for Genomic Discovery, expanding its clinical genomic dataset to drive precision medicine.
Alnylam Pharmaceuticals News Analytics from Thu, 01 May 2025 07:00:00 GMT to Sat, 01 Nov 2025 17:02:57 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -4
